Misotac vs Combined Oral Contraceptive Pill in the Treatment of Symptomatic Isthmocele

• Status: Not yet recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Isthmocele is a growing concern as a cause of abnormal uterine bleeding, especially post menstrual bleeding which may be present in up to 82% of these cases (Iannone et al 2019).

our trial is a randomized clinical trial in which women will be randomly allocated to either medical treatment by oral contraceptive or to medical treatment by misotac.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University Hospital

Criteria

Inclusion Criteria:

• Women with a previous cesarean section

• who presented with postmenstrual spotting,

• sonohysterography had shown a isthmocele

Exclusion Criteria:

• Pregnancy,

• (suspected) malignancies,

• use of any hormonal contraceptives,

• fibroid,

• infection in the genital tract